Duetact Takeda Pharmaceuticals North America, Inc. - Treatment for Type 2 Diabetes

Duetact is a combination of pioglitazone, which directly targets insulin resistance, and glimepiride, a sulfonylurea that acts primarily by increasing the amount of insulin produced by the pancreas. Duetact is indicated for the treatment of type 2 diabetes.

Posted: July 2006

Related Articles:

Duetact (pioglitazone HCl and glimepiride) FDA Approval History

View comments

Hide
(web4)